PDL BioPharma Competitors

PDL BioPharma (NASDAQ:PDLI) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk & Volatility

PDL BioPharma has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for PDL BioPharma and Amgen, as provided by MarketBeat.com.

Amgen has a consensus target price of $257.3043, indicating a potential upside of 15.95%. Given Amgen's higher possible upside, analysts clearly believe Amgen is more favorable than PDL BioPharma.

Earnings & Valuation

This table compares PDL BioPharma and Amgen's gross revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than PDL BioPharma. PDL BioPharma is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

86.2% of PDL BioPharma shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 2.2% of PDL BioPharma shares are owned by company insiders. Comparatively, 0.4% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares PDL BioPharma and Amgen's net margins, return on equity and return on assets.

Summary

Amgen beats PDL BioPharma on 10 of the 13 factors compared between the two stocks.

PDL BioPharma (NASDAQ:PDLI) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk & Volatility

PDL BioPharma has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Institutional & Insider Ownership

86.2% of PDL BioPharma shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 2.2% of PDL BioPharma shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for PDL BioPharma and Gilead Sciences, as provided by MarketBeat.com.

Gilead Sciences has a consensus target price of $96.0370, indicating a potential upside of 51.89%. Given Gilead Sciences' higher possible upside, analysts clearly believe Gilead Sciences is more favorable than PDL BioPharma.

Earnings & Valuation

This table compares PDL BioPharma and Gilead Sciences' gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than PDL BioPharma. PDL BioPharma is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PDL BioPharma and Gilead Sciences' net margins, return on equity and return on assets.

Summary

Gilead Sciences beats PDL BioPharma on 9 of the 13 factors compared between the two stocks.

PDL BioPharma (NASDAQ:PDLI) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Volatility & Risk

PDL BioPharma has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Institutional and Insider Ownership

86.2% of PDL BioPharma shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 2.2% of PDL BioPharma shares are owned by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares PDL BioPharma and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than PDL BioPharma. PDL BioPharma is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for PDL BioPharma and Vertex Pharmaceuticals, as provided by MarketBeat.

Vertex Pharmaceuticals has a consensus target price of $292.68, suggesting a potential upside of 40.85%. Given Vertex Pharmaceuticals' higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than PDL BioPharma.

Profitability

This table compares PDL BioPharma and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Vertex Pharmaceuticals beats PDL BioPharma on 12 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and PDL BioPharma (NASDAQ:PDLI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of PDL BioPharma shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of PDL BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for Regeneron Pharmaceuticals and PDL BioPharma, as reported by MarketBeat.com.

Regeneron Pharmaceuticals presently has a consensus price target of $625.8077, suggesting a potential upside of 39.26%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than PDL BioPharma.

Risk & Volatility

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, PDL BioPharma has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and PDL BioPharma's revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than PDL BioPharma. PDL BioPharma is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and PDL BioPharma's net margins, return on equity and return on assets.

Summary

Regeneron Pharmaceuticals beats PDL BioPharma on 12 of the 14 factors compared between the two stocks.

PDL BioPharma (NASDAQ:PDLI) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Valuation & Earnings

This table compares PDL BioPharma and Biogen's gross revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than PDL BioPharma. Biogen is trading at a lower price-to-earnings ratio than PDL BioPharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PDL BioPharma and Biogen's net margins, return on equity and return on assets.

Volatility and Risk

PDL BioPharma has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Institutional & Insider Ownership

86.2% of PDL BioPharma shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 2.2% of PDL BioPharma shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for PDL BioPharma and Biogen, as provided by MarketBeat.

Biogen has a consensus price target of $304.4667, suggesting a potential upside of 15.52%. Given Biogen's higher possible upside, analysts clearly believe Biogen is more favorable than PDL BioPharma.

Summary

Biogen beats PDL BioPharma on 9 of the 13 factors compared between the two stocks.

PDL BioPharma (NASDAQ:PDLI) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Institutional and Insider Ownership

86.2% of PDL BioPharma shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 2.2% of PDL BioPharma shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares PDL BioPharma and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

PDL BioPharma has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for PDL BioPharma and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential upside of 3.14%. Given Alexion Pharmaceuticals' higher possible upside, analysts plainly believe Alexion Pharmaceuticals is more favorable than PDL BioPharma.

Valuation and Earnings

This table compares PDL BioPharma and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than PDL BioPharma. PDL BioPharma is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Alexion Pharmaceuticals beats PDL BioPharma on 14 of the 14 factors compared between the two stocks.